Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

The mechanism of GLP-1 agonists is straightforward. They mimic the effects of the naturally occurring hormone, GLP-1, which regulates blood sugar and appetite in the body. While they are highly ...

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

Recombinant protein expression lies at the heart of modern biotechnology and biopharmaceutical production. For decades, the field has relied primarily on two established expression systems namely ...

If you thought September was huge for M&As in the biopharma space, you didn’t see October coming. Nine major M&As were signed, with most of them being multi-billion-dollar deals in various therapeutic ...

Today, AAVantgarde Bio raises $141 million (€122 million) in a series B round to advance its gene therapy programs for inherited eye diseases, marking one of Europe’s largest private financings in ...